

# PARTICIPATE IN EXCITING NEW RESEARCH AT THE BOSTON UNIVERSITY SCHOOL OF MEDICINE ALZHEIMER'S DISEASE CENTER (BUADC)



World-renowned Alzheimer's research center funded by the National Institutes of Health

Many studies are being conducted now, some to test promising new drugs to treat Alzheimer's. Thank you for joining a study!

# CLINICAL RESEARCH AT BUADC PROVIDES MANY BENEFITS FOR PARTICIPANTS

- Extensive testing (for free) to diagnose whether you have Mild Cognitive Impairment (MCI), Alzheimer's disease, or no dementia-related symptoms.
- Ongoing health monitoring and additional testing, free of cost.
- Access to potential treatments before they are widely available. For most clinical trials, individuals
  on the placebo can go on the "active drug" if it is proving to be beneficial BEFORE it is
  FDA-approved during the "open" part of the study.
- Reimbursement for your travel costs. The BUADC can also arrange transportation for you.
- Participation in a study can help bring a sense of connection to those involved and an affirmation that you are not alone. Most importantly, research gives us all HOPE!

### WHO WE ARE LOOKING FOR

- People with a range of memory complaints, including those diagnosed with Alzheimer's disease or Mild Cognitive Impairment (MCI).
- Healthy participants, not just individuals already showing signs of memory loss, so that we can better understand the earlier stages of the disease before symptoms are noticeable.

# CLINICAL TRIALS FOR 3 NEW DRUGS: WHAT YOU CAN EXPECT AS A PARTICIPANT

The BUADC is testing 3 different drugs that researchers hope can actually slow down the development of Alzheimer's, significantly modifying the course of the disease. After extensive testing (for free), BUADC will recommend which clinical trial you are best suited for based on your symptoms and diagnosis. If enrolled, you will receive either the new drug or a placebo.

### **CLINICAL TRIALS...** Range from 18 months to 3 years.

Require you to visit the BUADC in Boston once a month (every 2 weeks for the 18 month trial). Can vary from 45 minutes to all day, per visit.

Requires a "study partner" (family member or close friend) to accompany you to your visits.

### 1. CLINICAL TRIAL TO TEST A NEW DRUG, BAN2401 // CURRENTLY ONGOING

Participants age 50-90 with Mild Cognitive Impairment (MCI) or very early Alzheimer's disease.

### 2. TWO CLINICAL TRIALS TO TEST A NEW DRUG, SOLANEZUMAB // RECRUITMENT STARTED JAN 2014

Participants age 65-85 who have "preclinical" memory complaints AND age 55-90 who have diagnosed "mild" Alzheimer's disease. Both trials require a study partner to accompany you to study visits.

**3. CLINICAL TRIAL TO TEST A NEW DRUG, TCAD (AN ORAL MEDICATION)** // RECRUITMENT STARTS APPROX. MAR 2014 Participants with moderate dementia due to Alzheimer's disease.

# OTHER STUDIES: WHAT YOU CAN EXPECT AS A PARTICIPANT

Many other studies, including the 2 highlighted below, are being conducted at the BUADC in order to understand Alzheimer's disease and its progression more clearly and determine easier and more cost-effective ways to diagnose the disease.

STUDIES... Range from a one-time visit to one visit per year.

Take place at the BUADC site in Boston.

Can vary in length per visit.

May require blood draw and/or spinal tap and/or imaging.

# PLEASE LET THE BUADC KNOW if you have any limitations on your time commitment and we can place you in an appropriate trial or study that meets your needs.

### 1. AVID PET SCAN STUDY // RECRUITMENT STARTS APPROX. MAR 2014

PET scans help determine whether an individual has Alzheimer's disease. The safe procedure, which has been approved by the FDA, costs approximately \$2,000 and is currently not paid for by Medicare. This groundbreaking study is using a new PET scan technique to measure the amounts of abnormal tau and amyloid proteins in the brain.


### 2. DIAGNOSTIC STUDY AIMING TO DEVELOP A BLOOD TEST FOR ALZHEIMER'S DISEASE // CURRENTLY ONGOING

Participants age 50-85 who are healthy, have been diagnosed with Mild Cognitive Impairment (MCI), or have been diagnosed with Alzheimer's disease.

# THE BUADC'S COMMITMENT TO YOU

- Research participation is always under strict review by committees to make sure the safety and well-being of participants is the most important priority.
- Participation in research always requires consent by the volunteer after being informed of all the procedures, any risks and benefits.
- All personal information provided to us by the research participant is kept completely confidential.

"All of us at **Senior Living Residences (SLR)** and our **Compass Memory Support Neighborhoods**® are proud to be affiliated with the dedicated professional team at the BUADC, led by Dr. Bob Stern. With the unflagging support of our residents' families for over 20 years, our passion has been to increase the public understanding of Alzheimer's and to support research toward better treatment options and eventually a cure. Please add your own passion to this noble cause, and volunteer to participate in a BUADC study of your choice."







"The single most important thing anyone can do to have an impact on the Alzheimer's disease crisis is to volunteer to participate in research. Promising new research is a cause for hope."

ROBERT STERN, PhD.

Director of the Clinical Core

Boston University School of Medicine Alzheimer's Disease Center